This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werngren, J.
Right arrow Articles by Hoffner, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werngren, J.
Right arrow Articles by Hoffner, S. E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2006, p. 2130-2132, Vol. 44, No. 6
0095-1137/06/$08.00+0     doi:10.1128/JCM.02218-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Evaluation of a Novel Kit for Use with the BacT/ALERT 3D System for Drug Susceptibility Testing of Mycobacterium tuberculosis

Jim Werngren,1,2* Lisbeth Klintz,1 and Sven E. Hoffner1

Department of Bacteriology, Swedish Institute for Infectious Disease Control (SMI), Solna, and Microbiology and Tumor Biology Center, Karolinska Institute, Solna, Sweden

Received 21 October 2005/ Returned for modification 11 March 2006/ Accepted 26 March 2006

We evaluated a new protocol for the BacT/ALERT MB susceptibility test (bioMérieux Inc., Durham, NC) using 80 Mycobacterium tuberculosis WHO challenge panel strains. The drug susceptibility profiles of these strains are well characterized, and consensus drug resistance results have been established after tests were performed at around 20 international reference laboratories using recommended reference drug susceptibility techniques. Strains were tested according to the bioMérieux protocol using the following critical concentrations: rifampin (RIF), 0.9 mg/liter; isoniazid (INH), 0.4 and 0.09 mg/liter; and ethambutol (EMB), 1.8 mg/liter. The BacT/ALERT system detected 36/37 RIF-resistant strains. For INH (low concentration), 59/59 resistant strains were detected, and for EMB, 34/34 resistant strains were detected. Thus, the sensitivities were 97%, 100%, and 100% for RIF, INH, and EMB, respectively. The corresponding specificities were 100%, 95%, and 98%, respectively, for the same drugs. As soon as the BacT/ALERT MP seed bottle flagged positive, the median time to obtain a susceptibility results was 7.8 days. The results show good concordance with the consensus results of the international reference laboratories and demonstrate that BacT/ALERT 3D should be considered as an alternative method for rapid and automated drug susceptibility testing of M. tuberculosis.

* Corresponding author. Mailing address: Swedish Institute for Infectious Disease Control, Department of Bacteriology, S-171 82 Solna, Sweden. Phone: 46 8 4572473. Fax: 46 8 301797. E-mail: jim.werngren{at}smi.ki.se.

Journal of Clinical Microbiology, June 2006, p. 2130-2132, Vol. 44, No. 6
0095-1137/06/$08.00+0     doi:10.1128/JCM.02218-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Singh, P., Wesley, C., Jadaun, G. P. S., Malonia, S. K., Das, R., Upadhyay, P., Faujdar, J., Sharma, P., Gupta, P., Mishra, A. K., Singh, K., Chauhan, D. S., Sharma, V. D., Gupta, U. D., Venkatesan, K., Katoch, V. M. (2007). Comparative Evaluation of Lowenstein-Jensen Proportion Method, BacT/ALERT 3D System, and Enzymatic Pyrazinamidase Assay for Pyrazinamide Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45: 76-80 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»